Literature DB >> 14627876

Attention-deficit/hyperactivity disorder: increased costs for patients and their families.

Andrine R Swensen1, Howard G Birnbaum, Kristina Secnik, Maryna Marynchenko, Paul Greenberg, Ami Claxton.   

Abstract

OBJECTIVE: To estimate the direct (medical and prescription drug) and indirect (work loss) costs of children treated for attention-deficit/hyperactivity disorder (ADHD) and their family members.
METHOD: The data source was an administrative database from a national, Fortune 100 manufacturer that included all medical, pharmaceutical, and disability claims for beneficiaries (n > 100,000). The analysis involved four samples. The ADHD patient sample included individuals age 18 or younger with at least one ADHD claim during the study period (1996-1998). Resource utilization of ADHD patients was contrasted with a matched control sample of patients who did not have claims for ADHD. The ADHD and non-ADHD family samples included non-ADHD family members of ADHD patients and their matched controls.
RESULTS: The annual average expenditure (direct cost) per ADHD patient was $1,574, compared to $541 among matched controls. The annual average payment (direct plus indirect cost) per family member was $2,728 for non-ADHD family members of ADHD patients versus $1,440 for family members of matched controls. Both patient and family cost differences were significant at the 95% confidence level.
CONCLUSIONS: ADHD imposes a significant financial burden regarding the cost of medical care and work loss for patients and family members.

Entities:  

Mesh:

Year:  2003        PMID: 14627876     DOI: 10.1097/00004583-200312000-00008

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  58 in total

1.  The importance of parental attributions in families of children with attention-deficit/hyperactivity and disruptive behavior disorders.

Authors:  Charlotte Johnston; Jeneva L Ohan
Journal:  Clin Child Fam Psychol Rev       Date:  2005-09

Review 2.  Racial, ethnic, and language disparities in early childhood developmental/behavioral evaluations: a narrative review.

Authors:  Katharine E Zuckerman; Kimber M Mattox; Brianna K Sinche; Gregory S Blaschke; Christina Bethell
Journal:  Clin Pediatr (Phila)       Date:  2013-09-10       Impact factor: 1.168

Review 3.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Financial burden for families of children with special health care needs.

Authors:  Karen Kuhlthau; Kristen Smith Hill; Recai Yucel; James M Perrin
Journal:  Matern Child Health J       Date:  2005-06

5.  Validity of the health-related quality of life assessment in the ADORE study: Parent Report Form of the CHIP-Child Edition.

Authors:  Anne W Riley; David Coghill; Christopher B Forrest; Maria J Lorenzo; Stephen J Ralston; Georg Spiel
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-12       Impact factor: 4.785

6.  Pediatric Anxiety Disorders: A Cost of Illness Analysis.

Authors:  Jeffrey E Pella; Eric P Slade; Paige J Pikulski; Golda S Ginsburg
Journal:  J Abnorm Child Psychol       Date:  2020-04

7.  Caregiver Preferences Regarding Personal Health Records in the Management of ADHD.

Authors:  Sarah D Ronis; Constance D Baldwin; Scott McIntosh; Kenneth McConnochie; Peter G Szilagyi; James Dolan
Journal:  Clin Pediatr (Phila)       Date:  2015-01-07       Impact factor: 1.168

8.  What influences clinicians' decisions about ADHD medication? Initial data from the Influences on Prescribing for ADHD Questionnaire (IPAQ).

Authors:  Hanna Kovshoff; May Vrijens; Margaret Thompson; Lucy Yardley; Paul Hodgkins; Edmund J S Sonuga-Barke; Marina Danckaerts
Journal:  Eur Child Adolesc Psychiatry       Date:  2013-03-02       Impact factor: 4.785

9.  White matter microstructure in subjects with attention-deficit/hyperactivity disorder and their siblings.

Authors:  Katherine E Lawrence; Jennifer G Levitt; Sandra K Loo; Ronald Ly; Victor Yee; Joseph O'Neill; Jeffry Alger; Katherine L Narr
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2013-03-07       Impact factor: 8.829

10.  Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder?

Authors:  Oscar G Bukstein; L Eugene Arnold; Jeanne M Landgraf; Paul Hodgkins
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2009-12-10       Impact factor: 3.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.